Changeflow GovPing Healthcare & Life Sciences Patent Application for Dispersible Pharmaceutic...
Routine Notice Added Draft

Patent Application for Dispersible Pharmaceutical Formulations

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published patent application US20260083690A1 concerning dispersible pharmaceutical formulations of a specific chemical compound. The application details the composition and potential uses of these formulations.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO for a new pharmaceutical formulation. The application, identified as US20260083690A1, describes dispersible pharmaceutical compositions containing N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and optionally a pharmaceutically acceptable carrier.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on drug manufacturers. However, it represents a step in the intellectual property protection process for novel drug formulations, which could impact future market exclusivity and product development strategies for pharmaceutical companies.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF

Application US20260083690A1 Kind: A1 Mar 26, 2026

Inventors

Kristin PATTERSON, Jiping LIU

Abstract

The present disclosure relates to dispersible pharmaceutical compositions comprising N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

CPC Classifications

A61K 31/167 A61K 9/0056 A61K 9/16 A61K 9/2013 A61K 9/2018 A61K 9/2054 A61K 9/2072

Filing Date

2025-06-11

Application No.

19234475

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
June 11th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083690A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Pharmaceutical Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!